June 17, 2022

 

VIA EDGAR

 

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 

Attention: Laura Crotty
Phone: (202) 394-0334
   
Re: RetinalGenix Technologies Inc. Application for Withdrawal on Form AW
 

pursuant to Rule 477 of the Securities Act of 1933, as amended,

of Post-Effective Amendment No. 2 to the Registration Statement on Form S-1

 

Ladies and Gentlemen:

 

Pursuant to Rule 477 (a) of the Securities Act of 1933, as amended, RetinalGenix Technologies Inc. (the “Registrant”) hereby respectfully requests the immediate withdrawal of the Registrant’s Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 (the “Amendment”), filed with the Commission on June 13, 2022.

 

As discussed with SEC staff members, the Registrant is requesting the withdrawal of the Amendment because the Amendment references and was filed under an incorrect File Number, 333-262282. No securities have been sold in connection with the Amendment.

 

 

  Very truly yours,
  RetinalGenix Technologies Inc.
     
  By: /s/ Jerry Katzman
  Name: Jerry Katzman
  Title: President, Secretary, Treasurer and Director
    (Principal Executive Officer and Principal Financial Officer and Accounting Officer)

 

 

 

 

 

 

Retinalgenix Technologies (QB) (USOTC:RTGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos Retinalgenix Technologies (QB).
Retinalgenix Technologies (QB) (USOTC:RTGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos Retinalgenix Technologies (QB).